Navigation Links
NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
Date:4/1/2009

's second collaboration with a worldwide market leader after our alliance with Alcon in the ophthalmic, otic and sinusitis fields. We expect to maintain a low cash burn in 2009 as we work closely with our partners that fund clinical development costs, and as we focus investment on developing our earlier-stage internal pipeline programs for which we anticipate proof-of-concept data later this year."

2008 and Recent Highlights

  • Ophthalmic: NovaBay continues to work closely with Alcon, Inc. to commercialize Aganocide compounds to treat infections of the eye, ear and sinus, and to develop the next generation of contact lens solutions. Alcon recently initiated a Phase I clinical trial of NVC-422 (N,N-dichloro-2,2-dimethyltaurine), NovaBay's lead Aganocide compound, after receiving clearance of an Investigational New Drug (IND) application from the U.S. Food and Drug Administration in January 2009. The IND clearance triggered an immediate milestone payment of $1 million from Alcon to NovaBay.

  • Dermatology: In March 2009, NovaBay announced a global agreement with Galderma, S.A. to develop and commercialize Aganocides for large dermatological markets such as acne, impetigo and other conditions. Under the terms of the agreement, NovaBay expects to receive from Galderma up to $50 million upon achievement of certain development and regulatory milestones related to the acne and impetigo indications and escalating double digit royalties on future net sales of products. Galderma will be responsible for the development costs of the acne and other indications, except in Japan, and for the ongoing development program for impetigo, upon the achievement of a specified milestone. NovaBay also announced in March new data presented at the American Academy of Dermatology 67th Annual Meeting that showed NVC-422 achieved significant clinical and myco
    '/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBays Novel Aganocide Drugs for Major Dermatological Conditions
2. NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock
3. Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K
4. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
5. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
6. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
7. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
9. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
10. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
11. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 Shimadzu Scientific ... Chromatograph (2D-LC), which offers a powerful separation ... The system provides a new level of ... is beneficial to scientists analyzing pharmaceutical impurities, ... products. , Comprehensive 2D-LC combines two independent ...
(Date:9/17/2014)... , Sept. 17, 2014 BioClinica®, Inc., ... eClinical Solutions, today announced three of its experts are ... for Clinical Data Management to be held September 28 ... . The Company also announced the innovative ... overall quality in clinical trials acquired earlier this year, ...
(Date:9/17/2014)... Hussey Copper , a leader in ... copper, announces Gilmour Academy Ice Arena,s conversion of more ... solid touch surface to help protect against bacteria.  MD-Cu ... that kills greater than 99.9% of MRSA, E-coli and ... , Innovative Gilmour Academy ...
(Date:9/17/2014)... RXi Pharmaceuticals Corporation (NASDAQ: ... developing and commercializing innovative therapies addressing major unmet ... has been granted a patent by the United ... delivery system for delivering its "original" RNAi compounds ... treatment of diseases with an inflammatory component. Potential ...
Breaking Biology Technology:Shimadzu’s New Nexera-e Two Dimensional Comprehensive Liquid Chromatograph Empowers Laboratories to Separate Even the Most Complex Mixtures 2BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4
... 25 Scimitar Equity, LLC issues a ... VOQP), entitled,"Creating Value; Turnaround Leverages Product Opportunities ... review is available at website: http://www.scimitarequity.com ... Jersey-based biotechnology company,dedicated to becoming a recognized ...
... 25 Mymetics,Corporation (OTC: MYMX), will be holding an ... PM New York Time to update all shareholders,on the ... Form 10-Q and to,address recent press articles., You ... at +1-866-591-4361 PIN 815,726 and from Europe at +41-800-329-326 ...
... 23 Eisai Corporation of,North America and its ... Food and Drug Administration (FDA) has approved a ... prevention of,chemotherapy-induced nausea and vomiting (CINV). ALOXI Capsules ... prevention of acute nausea and,vomiting following initial and ...
Cached Biology Technology:VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC 2FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting 2FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting 3
(Date:9/16/2014)... The 36 Pit Fire began on September 13, 2014. ... It is currently over 2,300 acres in size and ... The 36 Pit Fire was calm Monday night due to ... establishing an anchor point and beginning to construct a fireline ... The following resources are working on the fire: , 7 ...
(Date:9/16/2014)... same viruses that make us sick can take up ... a sneeze, cough or other troublesome symptom, according to ... St. Louis. , On average, healthy individuals carry ... researchers report online in BioMed Central Biology . ... the diversity of viruses in healthy people. , ...
(Date:9/16/2014)... for the dinosaurs 66 million years ago decimated the ... extent than their deciduous peers, according to a study ... the journal PLOS Biology . , Applying ... fossilized leaves of angiosperms flowering plants excluding ... ecology of a diverse plant community thriving during a ...
Breaking Biology News(10 mins):Healthy humans make nice homes for viruses 2Healthy humans make nice homes for viruses 3Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4
... percent as compared to last year,s record size. According to measurements ... 27.7 million tonnes, compared to the 2006 record ozone loss of ... area and the depth of the ozone hole. The area of ... 220 Dobson Units is 24.7 million sq km, roughly the ...
... vaccine delivered through painless microneedles in patches applied ... to delivery through hypodermic needles, according to researchers ... Technology. Using new grants from the National Institutes ... five years, researchers from the two institutions plan ...
... help may be on the way for beleaguered growers ... Many varieties of the widely grown bottlegourd (Lagenaria siceraria) ... (ZYMV), a scourge of commercial cucurbits that includes pumpkins, ... ZYMV infects cucurbits throughout North America and in other ...
Cached Biology News:2007 ozone hole 'smaller than usual' 22007 ozone hole 'smaller than usual' 3Flu vaccine in painless skin patches under development at Emory, Georgia Tech with NIH grants 2Battling virus disease of watermelon with bottlegourds 2
HOXC11 Antibody...
HOXC11 Antibody...
PPOX Immunogen: PPOX (AAH02357, 378 a.a. ~ 478 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit anti MMP-13, Hinge Region MMP-13 Hinge Region...
Biology Products: